FDA First Amendment meeting
Executive Summary
FDA may hold a public meeting regarding its May 16 request for comments on the agency's commercial speech policy, FDA says in an Aug. 12 letter to Sen. Jack Reed (D-R.I.), who suggested the meeting. "We have not yet decided whether to hold a public meeting or series of meetings on these issues, although that idea is certainly worth considering," the letter says. FDA is accepting comments until Sept. 13, and will accept rebuttal comments until Oct. 28 (1"The Pink Sheet" May 20, p 14)...
You may also be interested in...
FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?
FDA is requesting comment on the legal underpinnings for arguing that promotions of prescription drugs can be more tightly regulated than those for other products
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.
ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.